Trinity Biotech (NASDAQ:TRIB) is one of the few names remaining in the Med-Tech space that's not only reasonably priced, but has a number of catalysts coming up over the next 12-18 months.
For those who are not familiar with the name, Trinity Biotech is a diagnostic company which attains a substantial portion of its revenue from point-of-care diagnostics and clinical diagnostics systems. As you can see from the table below, the company has grown revenue for each of the past two years, albeit at a mid single digit rate.
|Point of Care||$16m||$17m||$19m|
|Clinical Diagnostic Systems||45m||50m||54m|
|Life Science Supply||12m||11m||10m|
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|